BioDuro, Atombeat Join Forces to Speed Up Peptide Drug Discovery
This partnership will leverage BioDuro’s expertise and Atombeat’s in silico modeling know-how to launch an AI-powered platform that allows for accelerated development of next-generation peptides.
A strategic collaboration between contract research, development, and manufacturing organization (CRDMO), BioDuro, and artificial intelligence (AI) drug discovery specialist, Atombeat, has been formed to speed up peptide innovation. The partnership will combine Atombeat’s in silico modeling expertise, AI-accelerated and data-driven design platform with BioDuro’s discovery chemistry, biology, and drug metabolism and pharmacokinetics (DMPK) expertise for the development of next-generation peptides (1).
Atombeat’s AI-driven drug discovery approach comprises its proprietary Hermite software and RiDYMO platform, which are enhanced by technologies, such as Reinforced Dynamics, Uni-Dock, Uni-FEP, and Uni-QSAR. These technologies are capable of exploring a digital library of over one trillion potential peptide compounds through advanced computer modeling, AI, and specialized data. As this data exploration happens prior to any lab testing and filters and prioritizes the data based on key developability traits, the early stages of drug discovery are sped up, allowing scientists to focus on the most promising candidates.
After completion of the design phase, BioDuro utilizes its high-throughput synthesis capability to produce hundreds of peptide compounds. With this approach, it is possible to deliver high-purity, ready for biological testing peptides that do not require purification within one week.
“We are excited to advance peptide innovation through our strategic partnership with Atombeat. Atombeat brings extensive experience in AI-assisted drug design and optimization,” said Dr. Armin Spura, CEO of BioDuro, in a company press release (1). “Together, we aim to provide the industry with leading services in peptide drug development, accelerating smarter and more efficient peptide research, and delivering faster and comprehensive solutions to our global clients.”
“BioDuro's deep expertise in peptide synthesis and testing complements our strengths in AI-driven drug design exceptionally well,” added Dr. Dongdong Wang, co-founder of Atombeat, in the press release (1). “By integrating AI with experimental processes, we are committed to building an intelligent, integrated platform for peptide drug discovery and evaluation. Our shared commitment is to drive innovation in pharmaceutical development and help meet unmet clinical needs worldwide.”
This latest partnership comes shortly after BioDuro announced another collaboration with Silicogenix (SGX), which is aimed at accelerating drug discovery of novel drugs for complex diseases. In this partnership, the companies will combine BioDuro’s drug discovery platform with SGX’s novel frameworks to reduce costs and shorten timelines in the development of complex therapies (2).
“We are focused on the continued innovation of our fully integrated services to help meet growing demand for early drug discovery,” commented Dr. Subas Sakya, Chief Scientific Officer at BioDuro, in a company press release (2). “We are excited to partner with SGX to enable an alternative path for new drug discovery, propelling first-in-class therapeutics with the potential to save lives.”
“This is a pivotal moment for the biopharmaceutical industry, and this partnership is a significant step forward for how novel treatments for complex and rare diseases can be quickly brought to market,” noted Dr. Shailesh Date, Co-founder of SGX, in the press release (2). “BioDuro is an undisputed leader and we believe our collective approach will help biopharmaceutical companies greatly expedite the development cycle for therapeutics that address unmet medical needs.”
References
BioDuro. BioDuro and Atombeat Announce Partnership to Launch an AI-Powered Platform for Accelerated Peptide Drug Discovery. Press Release, July 30, 2025.
BioDuro. BioDuro Partners with Silicogenix to Accelerate Novel Drug Discovery for Complex Diseases. Press Release, June 10, 2025.